Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4496 Comments
1686 Likes
1
Gayanne
Registered User
2 hours ago
Every detail is impressive.
👍 106
Reply
2
Carolus
Community Member
5 hours ago
If only I had noticed it earlier. 😭
👍 14
Reply
3
Nihir
Power User
1 day ago
This is exactly the info I needed before making a move.
👍 123
Reply
4
Moris
Power User
1 day ago
Anyone else here feeling the same way?
👍 82
Reply
5
Azaree
Active Contributor
2 days ago
Really could’ve done better timing. 😞
👍 179
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.